Based on our findings, we hypothesize that APC mutations may similarly cooperate with driver mutations in oncogenic genes such as ALK, HNF1A, CDKN2A, HRAS, and EGFR to initiate an alternative oncogenic route leading to HCC in our study population. The gene discussed is HRAS; the disease is hepatocellular carcinoma.